Chemistry:Ethylbromazolam
Ethylbromazolam is a benzodiazepine derivative[1] which has been sold as a designer drug.[2][3][4] It is structurally similar to bromazolam, only differing by the substitution of the methyl group for an ethyl group on the triazole ring. It has been found in combination with its synthetic precursor desalkylgidazepam[5] in samples expected to contain alprazolam alone. Its global presence, analytical characterisation and GABAA receptor activity has been described by researchers at Linköping Univesity in collaboration with CanTEST, the Toronto Drug Checking Service, WEDINOS and others, finding ethylbromazolam has a similar in vitro potency to bromazolam.[6]
History
Ethylbromazolam has an extremely limited history of human usage. Very little is known about its pharmacological properties, metabolism, and potential toxicity.
It was first detected in Canada by the Toronto Drug Checking Service in November 2024,[6] then in the United Kingdom at WEDINOS in January 2025,[6][7] and has subsequently been detected in New Zealand in March 2025[2] and at CanTEST in April 2025.[3][6]
References
- ↑ "Ethylbromazolam". Cayman Chemicals. https://www.caymanchem.com/product/42723/ethylbromazolam.
- ↑ 2.0 2.1 "New benzodiazepine ethylbromazolam detected in New Zealand". High Alert. https://www.highalert.org.nz/alerts-and-notifications/new-benzodiazepine-ethylbromazolam-detected-in-new-zealand/.
- ↑ 3.0 3.1 "Ethylbromazolam and bromonordiazepam found in alprazolam pill". The Know. 28 April 2025. https://theknow.org.au/alerts_warnings/ethylbromazolam-and-bromonordiazepam-found-in-alprazolam-pill/.
- ↑ "Novel benzodiazepine found in counterfeit Xanax pressed pill and off-white powder". Assist Plus. 27 April 2025. https://assistplus.com.au/2025/04/27/novel-benzodiazepine-found-in-counterfeit-xanax-pressed-pill-and-off-white-powder/.
- ↑ "Ethylbromazolam and Bromonordiazepam Found in ‘Alprazolam’ Pill". CanTEST. 28 April 2025. https://cantest.com.au/wp-content/uploads/2025/05/28April2025-23.pdf.
- ↑ 6.0 6.1 6.2 6.3 "Global emergence and γ-aminobutyric acid type A (GABAA) receptor activity of the new designer benzodiazepine ethylbromazolam". Archives of Toxicology. May 2026. doi:10.1007/s00204-026-04433-9. PMID 42159737.
- ↑ "Philtre - February 2025". February 2025. https://wedinos.wales/app/uploads/sites/2/2025/04/Philtre_Feb_25.pdf.
 |  |
